04 dec: De bedste tennisferier
05 dec: Her er julegaven til hende
04-12-2008 14:45:00

Orbit International’s Power Group Receives New Orders Valued at Approximately $660,000

Orbit International Corp. (NASDAQ:ORBT), an electronics manufacturer,

systems integrator and software solution provider, today announced that

its Power Group, Behlman Electronics, Inc. (“Behlman”) has received two

new contract awards with an aggregate value of approximately $660,000.

The first order of approximately $240,000, supports a commercial power

supply used in flight safety training simulators. This represents a

follow-on order for these units which have been used for this

application for many years. However, this latest production release

represents the largest single order received for this application.

Deliveries under this contract award are expected to commence in the

first quarter of 2009 and be completed by the end of calendar 2009.

The second order of approximately $420,000 is for a COTS power supply

supporting a land based satellite communications system. Again, this

latest award represents a follow-on production requirement for these

power supplies, and is the second order received within the last several

months. Management believes its customer is experiencing greater demand

for its power supply than was originally forecast. This power supply is

part of an ongoing program for which Behlman expects to receive

additional orders in 2009 and beyond. Deliveries under this current

contract are expected to commence in the second quarter of 2009 and

continue through the fourth quarter of 2009.

The Company also announced that through November 30, 2008 Behlman has

already achieved record bookings for the second consecutive year.

Mark Tublisky, President of Behlman Electronics, Inc., stated,

“Behlman’s commitment as a power solutions provider has enabled our

Power Group to establish strong business relationships which have

positioned the Company in a number of long term production programs.

These customer relationships and program requirements have established a

clear path for our business growth, as we continue to introduce our

standard power products and power platforms to drive future business

opportunities.”

Dennis Sunshine, President and Chief Executive Officer of Orbit

International Corp., commented, “Behlman continues its record breaking

activity within the COTS and commercial power marketplace. Behlman’s

number of product platforms combined with its niche power solutions

business has enabled the Power Group to maintain strong sales despite

current economic conditions. This strong base of business has enabled

Behlman to achieve record annual bookings through the first eleven

months of 2008. With its increased backlog of new and follow on orders,

our Behlman management team anticipates a strong sales year for 2009.”

Sunshine continued, “The excellent year from our Power Group has

somewhat mitigated the impact of customer driven shipment delays and

contract timing issues experienced by our Electronics Group. We remain

confident, however, that the issues related to shipment delays will be

resolved in the ensuing months, and that several new production contract

awards that have been on hold, will be released. In addition, management

continues to explore opportunities that would enhance shareholder value.

In that regard, as of November 30, 2008, the Company has repurchased

133,280 shares at an average price of $2.81 under the repurchase program

authorized by our Board of Directors in August 2008.”

Orbit International Corp. is involved in the manufacture of customized

electronic components and subsystems for military and nonmilitary

government applications through its production facilities in Hauppauge,

New York, Quakertown, Pennsylvania and Louisville, Kentucky. Its Behlman

Electronics, Inc. subsidiary manufactures and sells high quality

commercial power units, AC power sources, frequency converters,

uninterruptible power supplies and associated analytical equipment. The

Behlman military division designs, manufactures and sells power units

and electronic products for measurement and display.

Certain matters discussed in this news release and oral statements made

from time to time by representatives of the Company including, but not

limited to, statements regarding any acquisition proposal and whether

such proposal or a strategic alternative thereto may be considered or

consummated; statements regarding our expectations of Orbit’s operating

plans, deliveries under contracts and strategies generally; statements

regarding our expectations of the performance of our business;

expectations regarding costs and revenues, future operating results

including all guidance amounts, additional orders, future business

opportunities and continued growth, may constitute forward-looking

statements within the meaning of the Private Securities Litigation

Reform Act of 1995 and the Federal securities laws. Although Orbit

believes that the expectations reflected in such forward-looking

statements are based upon reasonable assumptions, it can give no

assurance that its expectations will be achieved. Forward-looking

information is subject to certain risks, trends and uncertainties that

could cause actual results to differ materially from those projected.

Many of these factors are beyond Orbit International's ability to

control or predict. Important factors that may cause actual results to

differ materially and that could impact Orbit International and the

statements contained in this news release can be found in Orbit's

filings with the Securities and Exchange Commission including quarterly

reports on Form 10-Q, annual reports on Form 10-K, current reports on

Form 8-K and its other periodic reports and its registration statement

on Form S-3 containing a final prospectus dated January 11, 2006. For

forward-looking statements in this news release, Orbit claims the

protection of the safe harbor for forward-looking statements contained

in the Private Securities Litigation Reform Act of 1995. Orbit assumes

no obligation to update or supplement any forward-looking statements

whether as a result of new information, future events or otherwise.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
10 dec
VWS
Der er simpelhen så meget støj i marked omkring Vestas. Prøv at vurdere disse få tal, og din beslutn..
26
13 dec
FING-B
Hvem tør efterhånden investere på børsen, med dette ufatteligt ødelæggende shorting og naked-short v..
24
08 dec
ZEAL
Der er et stykke historie omkring Zealand Pharma som jeg ikke har set nogen analytikler eller andre ..
23
07 dec
VWS
Hold nu. Nu er de støjende skribenter endelig sendt i karantæne og der er en helt anden ro i debatte..
19
10 dec
VELO
  @djks Tak for dine altid velovervejede indlæg, som er af stor betydning for debatten, idet man som..
18
12 dec
BAVA
Prøver du at dække dig ind under Bavarian for at undgå at vi snakker om dine enorme tab i Matas og R..
17
10 dec
NOVO-B
En julehilsen fra alpehue, og  et "Olympic" tillykke til Novo, dens aktionærer og verdens diabetespa..
17
07 dec
VELO
Lidt spændende læsning og et overblik over det kæmpe potentiale som ligger i Veloxis.    https://www..
16
09 dec
VWS
Lad mig prøve vs. Vestas at tage "prispres" fra en anden side, for der er også prispres i USA !!   M..
14
07 dec
VWS
Lyt til amerikanerne. De ved trods alt hvad de taler om. Alle er vel enige om at PTC fortsætter uæn..
14

Novo-rival spår effekt af ugentligt GLP-1 på linje med Ozempics

13-12-2017 13:30:09
Novo Nordisks store franske rival Sanofi forudser, at dens ugentlige GLP-1-analog, Efpeglenatid, har en effekt på langtidsblodsukkeret, der er på linje Novos nye ugentlige diabetes 2-middel Ozempic, som tilhører samme lægemiddelklasse.Det fremgår af en præsentation under et analytikerarrangement onsdag, hvor Sanofi fremlægger sin forsknings- og udviklingsstrategi for de kommende år.Sanofi indledte..

Novo-rival er på vej med nye studier i fedme og leversygdommen NASH

13-12-2017 09:56:25
Novo Nordisks store franske rival, Sanofi, vil ligesom Novo i de kommende år også fokusere på udviklingen af fedmemedicin og medicin til behandling af leversygdommen, NASH.Det fremgår af en pressemeddelelse i forbindelse med et analytikerarrangement onsdag, hvor Sanofi vil præsentere sin forsknings- og udviklingsstrategi for de kommende år.Sanofis udviklingsindsats inden for forretningsområdet, di..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas får sin største ordre nogensinde i Indien - NY
2
Vestas rykker nærmere kæmpekontrakter i New Mexico og Texas
3
Aktier/tendens: Genmab og Vestas fortsætter i fokus
4
Vestas ejer mere end 5 pct. egne aktier efter opkøb
5
Onsdagens aktier: Genmab endnu engang til bunds i negativt marked

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
14. december 2017 03:22:54
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171124.1 - EUROWEB4 - 2017-12-14 03:22:54 - 2017-12-14 03:22:54 - 1 - Website: OKAY